2026 Oklahoma Thoracic Oncology Conference
(5.25 Credits)
Okana Resort & Indoor Waterpark
639 First Americans Boulevard, Oklahoma City, OK, United States
March 7, 2026
Organizing Committee:
Target Audience:
Learning Objectives:
Agenda
Saturday, March 7th, 2026
All timings are in Central Time (CDT, GMT-05:00) time.
07:00 AM - 08:00 AMRegistration, Breakfast, & Exhibits (Sunrise Ballroom 2)
08:00 AM - 08:10 AMWelcome ( Sunrise Ballroom 1)
08:10 AM - 08:50 AMSession 1: Peri-operative IO is the New Default-Where paradigms are shifting ( Sunrise Ballroom 1)
Session Chair:
Raid Aljumaily, MD
08:10 AM - 08:25 AM
Updates in perioperative treatment and Role of pathological response in early stage NSCLC
- Chul Kim, MD
08:25 AM - 08:37 AM
Case-based Discussion
- Amy Eberle, ARNP; Chul Kim, MD; Mohamed Hassan, MD; Matthew Reinersman, MD; Ranjit B Jasaraj, MD, MD; Raid Aljumaily, MD
08:38 AM - 08:50 AM
Case-based Discussion
- Matthew Reinersman, MD; Chul Kim, MD; Mohamed Hassan, MD; Amy Eberle, ARNP; Nishant Rajendra Tiwari, MD; Raid Aljumaily, MD
08:50 AM - 09:15 AMSession 2: EGFR: Single-Agent vs Combo “Amivantamab + Lazertinib vs Osimertinib: Combination Strategy vs Monotherapy for 1L EGFR exon 19/21 Mutations ( Sunrise Ballroom 1)
Session Chair:
Jonathan Dowell, MD
08:50 AM - 09:05 AM
Amivantamab + Lazertinib vs Osimertinib: Combination Strategy vs Monotherapy for 1L EGFR exon 19/21 Mutations
- Yasir Elamin, MD
09:05 AM - 09:15 AM
Panel Discussion
- Paul El Tomb, MD, MD; Irim Yasin, MD, MD; Hassan Kaleem, MD; Jordan Malie Morton, MD; Yasir Elamin, MD; Jonathan Dowell, MD
09:15 AM - 09:30 AMSession 3: KeyNote ( Sunrise Ballroom 1)
09:15 AM - 09:30 AM
KRAS in NSCLC: Drive to targeted therapies-Current Insights
- Nagla Abdel Karim, MD
09:30 AM - 10:00 AMSession 4: Screening & Risk: Beyond Pack-Years ( Sunrise Ballroom 1)
Session Chair:
Nirmal Choradia, MD
09:30 AM - 09:40 AM
Lung Cancer Screening 3.0: AI, Risk Models, and Incidentalomas – Who Actually Belongs in the Scanner?
- Nirmal Vimalchand Choradia, MD
09:40 AM - 09:50 AM
Risk-adapted screening, AI/radiomics, overdiagnosis, and incidental findings
- Raymond Osarogiagbon, MD
09:50 AM - 10:00 AM
Panel Discussion
- Mark Doescher, MD, MSPH; Nathaniel Moulton, MD; Raymond Osarogiagbon, MD; Houssein Youness, MD, MD; Nirmal Choradia, MD; Fawad Chaudry MD.,FCCP, MD
10:00 AM - 10:35 AMSession 5: Formal Debate – “Looking into the Future: ctDNA-MRD and Pathologic Response – Driving Escalation and De-escalation of Adjuvant Therapy in Early-Stage NSCLC” ( Sunrise Ballroom 1)
Session Chair:
L. Kyle Brett, MD
10:00 AM - 10:10 AM
Pro Position (MRD-positive = escalate (IO/TKI/ADC); MRD-negative = safely de-escalate)
- Aadel Chaudhuri, MD
10:10 AM - 10:20 AM
Con Position (Assay variability, lead-time bias, lack of de-escalation data, risk of undertreating curable disease)
- Amin Nassar, MD
10:20 AM - 10:25 AM
Audience Q&A with live polling
10:25 AM - 10:35 AM
Panel Discussion
- Aadel Chaudhuri, MD; Amin Nassar, MD; L. Kyle Brett, MD
10:35 AM - 10:45 AMBreak & Exhibits (Sunrise Ballroom 2)
10:45 AM - 11:15 AMSession 6: ADC Tsunami in NSCLC From T-DXd to Dato-DXd: Are ADCs the New TKIs? ( Sunrise Ballroom 1)
Session Chair:
Ashtin Taylor, PharmD, PharmD
10:45 AM - 10:55 AM
HER2/HER3 and TROP2 ADCs in metastatic NSCLC efficacy vs ILD and other toxicities.
- Ashtin Taylor, PharmD, PharmD
10:55 AM - 11:05 AM
Can Antibody–Drug Conjugates Replace Docetaxel in Non-Oncogene NSCLC in the Second Line?
- Fawzi F Abu Rous, MD
11:05 AM - 11:15 AM
Case-based Discussion
- Ajay Sheshadri, MD, MSCI; Maida Hafiz, MD; Fawzi F Abu Rous, MD; Joshua Glover, MD; Ashtin Taylor, PharmD, PharmD
11:15 AM - 11:50 AMSession 7: Lung Toxicity ( Sunrise Ballroom 1)
Session Chair:
Fawad Chaudry MD.,FCCP, MD
11:15 AM - 11:25 AM
ADC and ICI lung toxicity : Are we getting any better in diagnosing or managing
- Maida Hafiz, MD
11:25 AM - 11:35 AM
Pneumonitis on Novel ADCs from Phase 1 trials
- Falah Fayaz, MD
11:35 AM - 11:50 AM
Discussion
- Sarah K Hayward, PharmD; Maida Hafiz, MD; Debra Richardson, MD, Other; Ajay Sheshadri, MD, MSCI; Fawad Chaudry MD.,FCCP, MD
11:50 AM - 12:20 PMSession 8: SCLC: Changing Horizons The Last Two Years vs the Last 25 Years ( Sunrise Ballroom 1)
Session Chair:
Muhammad Furqan, MD
11:50 AM - 12:00 PM
Practice-changing data for the frontline setting and maintenance strategies in LS-SCLC & ES-SCLC; redefining SCLC care
- Nagla Abdel Karim, MD
12:00 PM - 12:10 PM
Tarlatamab and Tarlatamab-Based Combinations in SCLC
- Abdul Rafeh Naqash, MD
12:10 PM - 12:20 PM
Panel Discussion
- Bilal Ahmad, MD, MD; Nagla Abdel Karim, MD; Muhammad Furqan, MD; Abdul Rafeh Naqash, MD
12:20 PM - 01:20 PMLunch & Exhibits(Sunrise Ballroom 2) ; Product Theater sponsored by Amgen (Non CME Accredited) : The First and Only DLL3-Targeting Bispecific T-cell Engager (BiTE®) Therapy for 2L ES-SCLC - Sarah Karpen, PA ( Redbud Room)
01:20 PM - 01:50 PMSession 9: Education Forum (Non CME Accredited - supported by AstraZeneca) ( Sunrise Ballroom 1)
01:20 PM - 01:50 PM
History of EGFR, Importance of Testing, Driver of Disease-Data in Early Stages: indications, where we’ve been, importance of testing -Newer Treatment Options: 1st Line, beyond -Landscape & Data
- Siddhartha Devarakonda, MD
01:50 PM - 02:20 PM Binaytara's Efforts in Improving Cancer Care Disparities (Non CME Accredited)
02:20 PM - 02:30 PMBreak & Exhibits (Sunrise Ballroom 2)
02:30 PM - 03:00 PMSession 10: Interactive Multidisciplinary Case “Cases You’ll Actually See on Monday” ( Sunrise Ballroom 1)
Session Chair:
Abdul Rafeh Naqash, MD
02:30 PM - 02:45 PM
Case-based Discussion
- Firas Muhammad Jafri, MD; Nishant Rajendra Tiwari, MD; Abdul Rafeh Naqash, MD; Ashtin Taylor, PharmD, PharmD; Raid Aljumaily, MD
02:45 PM - 03:00 PM
Case-based Discussion
- Firas Muhammad Jafri, MD; Joshua Glover, MD; Ashtin Taylor, PharmD, PharmD; Raid Aljumaily, MD; Abdul Rafeh Naqash, MD
03:00 PM - 03:20 PMSession 11: Post-Lunch Warm-Up Panel Discussion ( Sunrise Ballroom 1)
Session Chair:
Clay T Reed, MD
03:00 PM - 03:20 PM
What Was the Most Practice-Changing Trial for You Last Year? & What Will You Actually Change on Monday?
- Bilal Ahmad, MD, MD; Firas Muhammad Jafri, MD; Raid Aljumaily, MD; Nirmal Choradia, MD; L. Kyle Brett, MD; Clay T Reed, MD
03:20 PM - 03:50 PMSession 12: Oligoprogression & SBRT ( Sunrise Ballroom 1)
Session Chair:
Tyler Gunter, MD
03:20 PM - 03:30 PM
Oligoprogression in Oncogene-Addicted NSCLC: Burn It, Switch It, or Layer On ADC?
- Biagio Ricciuti, MD
03:30 PM - 03:40 PM
Stereotactic RT vs systemic switch vs adding ADC on top of TKI
- Steven H Lin, MD, PhD
03:40 PM - 03:50 PM
Panel Discussion
- Biagio Ricciuti, MD; Steven H Lin, MD, PhD; Raid Aljumaily, MD; Tyler Gunter, MD
03:50 PM - 04:00 PMSession 13: Closing Panel & Synthesis and Takeaway ( Sunrise Ballroom 1)
Session Chair:
Raid Aljumaily, MD; Abdul Rafeh Naqash, MD; Clay T Reed, MD
Conference Chair
Abdul Rafeh Naqash, MD
Stephenson Cancer Center , University of Oklahoma
Raid Aljumaily, MD
University of Oklahoma
Clay T Reed, MD
Integris Cancer Institute
Session Chair
Ashtin Taylor, PharmD, PharmD
Stephenson Cancer Center , University of Oklahoma
Raid Aljumaily, MD
University of Oklahoma
Abdul Rafeh Naqash, MD
Stephenson Cancer Center , University of Oklahoma
Clay T Reed, MD
Integris Cancer Institute
Jonathan Dowell, MD
Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center
Tyler Gunter, MD
-
Nirmal Choradia, MD
University of Oklahoma
L. Kyle Brett, MD
Utica Park Clinic
Siddhartha Devarakonda, MD
Swedish/Providence
Fawad Chaudry MD.,FCCP, MD
University of Oklahoma
Muhammad Furqan, MD
Stephenson Cancer Center , University of Oklahoma
Faculty
Fawzi F Abu Rous, MD
Henry Ford Health
Maida Hafiz, MD
OU Health
Bilal Ahmad, MD, MD
-
Biagio Ricciuti, MD
Dana-Farber Cancer Institute
Steven H Lin, MD, PhD
The University of Texas MD Anderson Cancer Center
Firas Muhammad Jafri, MD
Oklahoma University Stephenson Cancer Center at Hillcrest
Irim Yasin, MD, MD
Integris Cancer Institute
Jordan Malie Morton, MD
-
Chul Kim, MD
-
Mohamed Hassan, MD
OUHSC
Amy Eberle, ARNP
OU Health
Debra Richardson, MD, Other
Debra Lynn Richardson, M.D., F.A.C.O.G., F.A.C.S
Nirmal Vimalchand Choradia, MD
Stephenson Cancer Center , University of Oklahoma
Yasir Elamin, MD
MD Anderson Cancer Center
Sarah K Hayward, PharmD
OU Health Stephenson Cancer Center
Falah Fayaz, MD
Stephenson Cancer Center , University of Oklahoma
Mark Doescher, MD, MSPH
-
Paul El Tomb, MD, MD
-
Joshua Glover, MD
University of Oklahoma
Hassan Kaleem, MD
-
Ajay Sheshadri, MD, MSCI
-
Raymond Osarogiagbon, MD
-
Nathaniel Moulton, MD
Integris Cancer Institute
Nagla Abdel Karim, MD
The George Washington University
Nishant Rajendra Tiwari, MD
Stephenson Cancer Center , University of Oklahoma
Ranjit B Jasaraj, MD, MD
Oklahoma University Health Science Center
Matthew Reinersman, MD
Stephenson Cancer Center , University of Oklahoma
Houssein Youness, MD, MD
The University of Oklahoma Health Sciences Center
Aadel Chaudhuri, MD
Washington University in St. Louis
This activity is supported with a Independent Medical Education grant from: Gilead
Accreditation
Exhibit & Sponsorship Information
If you are interested in exhibiting at this meeting or if your company is already exhibiting and informed you of a discounted badge rate, please visit our Exhibit Page for those details.